Background: Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed.
Case: A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response.
Conclusion: The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/AOG.0000000000004573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Merkel cell carcinoma is a rare neuroendocrine tumor with high mortality. It is well known that clonal integration of the Merkel cell polyomavirus into the dermal precursor cells is a hypothesized pathway in Merkel cell carcinoma pathogenesis. Here, we demonstrate a case of Merkel cell carcinoma (primary origin unknown) presenting with high Merkel cell polyomavirus DNA levels in swabs obtained from normal skin.
View Article and Find Full Text PDFSmall Cell Neuroendocrine Carcinoma of the Nasopharynx.
J Craniofac Surg
November 2024
Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Naval Medical University.
Background: Nasopharyngeal malignant tumors were relatively rare head and neck tumors with a low global incidence. There were various pathologic types of nasopharyngeal malignant tumors, and small cell neuroendocrine carcinoma (SCNEC) was a highly malignant subtype with rapid growth and early metastasis. SCNEC was rare in the nasopharynx, and its clinical presentation and treatment strategy were different from other types of nasopharyngeal malignancies, posing a challenge to clinicians.
View Article and Find Full Text PDFCervical Neuroendocrine Carcinoma Presenting as Isolated Large Ovarian Metastasis: A Case Report.
Am J Case Rep
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Dr Soetomo General Hospital, Universitas Airlangga, Surabaya, East Java, Indonesia.
BACKGROUND Neuroendocrine carcinoma (NEC) of the cervix is rare and has high mortality and recurrence rates. The clinical symptoms of cervical NEC, such as abnormal vaginal bleeding and discharge, are similar to those of other cervical cancers. Here, we describe a case involving a 42-year-old woman with cervical NEC accompanied by an isolated large ovarian metastasis.
View Article and Find Full Text PDFAnterior mediastinal tracheostomy - a salvage procedure for tracheal necrosis after thyroidectomy for medullary thyroid cancer: a case-report.
World J Surg Oncol
January 2025
Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.
A 34-year-old male patient with recently diagnosed with medullary thyroid carcinoma underwent total thyroidectomy and radical neck dissection, requiring sharp dissection to separate the tumour from the trachea. He required post operative intubation due to bilateral vocal cord paralysis. He developed ischaemic necrosis of the upper two thirds of the trachea presenting with marked surgical emphysema and an infective wound.
View Article and Find Full Text PDFSafety, Biodistribution, and Radiation Dosimetry of the Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors.
J Nucl Med
January 2025
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!